This continuing education activity will focus on treatment strategies for patients with multiple sclerosis, utilizing S1P-based therapeutics and combination therapy. Four expert faculty will review new and emerging clinical trial data of S1P-based therapeutics. The faculty will also discuss the data and rationale for utilizing combination therapeutics in managing patients with multiple sclerosis. A review of how to utilize the health care team and shared-decision making to achieve improved outcomes in MS patients will be discussed. Upon completion of this educational activity, clinicians will become better acquainted with treatment strategies utilizing S1P-based therapeutics and combination therapy when treating patients with multiple sclerosis.
Neurologist, primary care physicians, internists and advanced practice providers, including NPs and PAs, responsible for the diagnosis, treatment or management of patients with multiple sclerosis.
- Analyze the most current clinical trial data for newer S1P-based therapeutics
- Discuss the data and rationale for utilizing combination therapeutics in managing patients with multiple sclerosis
- Utilize the health care team and shared-decision making to achieve improved outcomes
Amit Bar-Or, MD
Presidential Endowed Professor
Department of Neurology
Director, Center for Neuroinflammation and Experimental Neurotherapeutics
Perelman School of Medicine
University of Pennsylvania
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Fred D. Lublin, MD||Consultant/Advisor: Abbvie; Acorda; Actelion; Apitope; Atara Biotherapeutics; Bayer HealthCare; Biogen; Brainstorm Cell Therapeutics; EMD Serono; Forward Pharma; GW Pharma; Innate Immunotherapeutics; Jazz Pharmaceuticals; Mapi Pharma; Medday; MedImmune; Novartis Pharmaceuticals Corp; Orion Biotechnology; Polpharma; Roche/Genentech; Receptos/Celgene; Regeneron; Sanofi/Genzyme; Teva; TG TherapeuticsGrant/Research Support: Actelion; Novartis Pharmaceuticals Corp; NMSS; Sanofi; Teva Neuroscience; Transparency Life Sciences|
|Amit Bar-Or, MD||Consultant/Advisor: Actelion; Atara Biotherapeutic; Biogen Idec; Celgene/Receptos; Genentech/Roche; MAPI; Medimmune; Merck/EMD Serono; Novartis, Sanofi-GenzymeGrant/Research Support: Novartis; Genentech|
|Mark S. Freedman, MD||Consultant/Advisor: Actelion; BayerHealthcare; BiogenIdec; Chugai; Clene Nanomedicine; EMD Canada; Genzyme; Hoffman La-Roche; MedDay; Merck Serono; Novartis Pharmaceuticals Corp; Sanofi-Aventis; Teva Canada InnovationGrant/Research Support: Genzyme Canada|
Speaker’s Bureau: Sanofi-Genzyme
|Clyde Markowitz, MD||Consultant/Advisor: Actelion; Bayer AG; Biogen; Celgene, EMD Serono, Inc.; Genentech/Roche; Genzyme/Sanofi; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission (ANCC) on Accreditation. AcademicCME’s ANCC provider number is P0491.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.
This activity has been supported by an independent educational grant from Actelion, a Janssen Pharmaceutical Company.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Actelion, a Janssen Pharmaceutical Company do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME inquiries or special needs, please contact [email protected].